ABSTRACT
Objective Enteric nervous system dysfunction is linked to digestive and neurological disorders. Hirschsprung’s disease (HSCR) is characterized by the loss of enteric neuron cells (ENCs) in the distal colon. Embryonic enteric neural crest cell (ENCC) migration defects contribute to HSCR development in some infants, but postnatal factors that regulate ENC fate are undetermined. We sought to establish how postnatal changes contribute to HSCR by profiling the colonic microenvironment of HSCR infants.
Design In this study, we recruited infants with HSCR, infants with anorectal malformations but normal ENC development (CT), and a group of age-matched healthy control subjects. Laboratory findings and clinical manifestations were recorded. Single-cell and spatial transcriptome sequencing were applied to colonic tissues from a sub-cohort of CT and HSCR infants. Patient specimens, a mouse model of neonatal ischemic enterocolitis, and Sox10 knockdown mouse (Sox10WT/MUT) were used to reveal the factors that lead to ENC loss in HSCR infants.
Results We discover that intestinal ischemia promotes CLDN1+ hypertrophic nerve trunk formation and ENC death. Mechanistically, ischemia leads to defective nitric oxide (NO) signaling in ENCs, which aggravates mitochondria damage and caspase-mediated apoptosis that can be ameliorated by a NO donor drug.
Conclusion We show that ischemia contributes to postnatal ENC loss in HSCR infants and suggest that NO donor drugs may alleviate ischemia-related ENC death.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was jointly supported by the National Natural Science Foundation of China (82125015 to Yuxia.Z., 81970450 to Yan.Z., 82100582 to W.L.), China Postdoctoral Science Foundation (2021TQ0083 to W.L.), Science and Technology Planning Project of Guangdong Province (2019B020227001 to H.X.), Guangdong Basic and Applied Basic Research Foundation (2021A1515220146 to Yan.Z.), and Guangzhou Basic Research Plan City School (Institute) Enterprise Joint Funding Project (SL2024A03J01 to Yan.Z.)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Medical Ethics Committee of Guangzhou Women and Children's Medical center gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
